LLY

1,022.27

-0.86%↓

JNJ

203.44

-1.28%↓

ABBV

230.28

+1.77%↑

UNH

335.94

+2.03%↑

AZN

90.46

-0.12%↓

LLY

1,022.27

-0.86%↓

JNJ

203.44

-1.28%↓

ABBV

230.28

+1.77%↑

UNH

335.94

+2.03%↑

AZN

90.46

-0.12%↓

LLY

1,022.27

-0.86%↓

JNJ

203.44

-1.28%↓

ABBV

230.28

+1.77%↑

UNH

335.94

+2.03%↑

AZN

90.46

-0.12%↓

LLY

1,022.27

-0.86%↓

JNJ

203.44

-1.28%↓

ABBV

230.28

+1.77%↑

UNH

335.94

+2.03%↑

AZN

90.46

-0.12%↓

LLY

1,022.27

-0.86%↓

JNJ

203.44

-1.28%↓

ABBV

230.28

+1.77%↑

UNH

335.94

+2.03%↑

AZN

90.46

-0.12%↓

Начало・Списък с акции・Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals Inc

Отворен

СекторЗдравеопазване

8.32 -0.48

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

8.2

Максимум

8.57

Ключови измерители
By Trading Economics
Приходи	11M -20M
Продажби	5.9M 40M
EPS	-0.19
Марж на печалбата	-49.569
Служители	184
EBITDA	16M -19M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+170.5% upside

Пазарни показатели
By TradingEconomics
Пазарна капитализация	153M 901M
Предишно отваряне	8.8
Предишно затваряне	8.32

Настроения в новините

By Acuity

50%

167 / 374 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

6.26 / 7.47 Подкрепа & съпротива

Day One Biopharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

3.12.2025 г., 23:21 ч. UTC

Печалби

Придобивния, сливания и поглъщания

EQB to Buy Loblaw Unit PC Financial for About $573.5 Million -- Update

3.12.2025 г., 23:14 ч. UTC

Придобивния, сливания и поглъщания

EQB to Buy PC Financial From Loblaw for About $573.5 Million

3.12.2025 г., 22:01 ч. UTC

Значими двигатели на пазара

Costco Wholesale Reports Higher Monthly Sales

3.12.2025 г., 21:38 ч. UTC

Печалби

Salesforce Raises Revenue Forecast as Agentforce Sales Top $500 Million

3.12.2025 г., 23:59 ч. UTC

Пазарно говорене

Australian Coal Prices Seen Having Recovered Well -- Market Talk

3.12.2025 г., 23:49 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

3.12.2025 г., 23:49 ч. UTC

Пазарно говорене

HSBC Chair Appointment Unlikely to Have Material Operational Impact -- Market Talk

3.12.2025 г., 23:49 ч. UTC

Пазарно говорене

Nikkei May Decline Amid Caution Over U.S. Labor Market -- Market Talk

3.12.2025 г., 23:13 ч. UTC

Пазарно говорене

Australian Treasurer Says Economy Not On Drip of Govt Spending -- Market Talk

3.12.2025 г., 23:10 ч. UTC

Печалби

Salesforce Raises Forecast as Agentforce Sales Top $500M -- Update

3.12.2025 г., 23:08 ч. UTC

Пазарно говорене

Goodman's New Bull Sees Profit Upgrade on Cards -- Market Talk

3.12.2025 г., 23:06 ч. UTC

Придобивния, сливания и поглъщания

EQB to Buy Loblaw Unit PC Financial for About $573.5M -- Update

3.12.2025 г., 22:59 ч. UTC

Придобивния, сливания и поглъщания

EQB to Buy PC Financial From Loblaw for About $573.5M

3.12.2025 г., 22:45 ч. UTC

Пазарно говорене

WiseTech Investor Day Increases Bull's Confidence -- Market Talk

3.12.2025 г., 22:20 ч. UTC

Печалби

Salesforce CEO: 9,500 of 18,500 Total Closed Agentforce Deals Are Paid

3.12.2025 г., 22:19 ч. UTC

Печалби

Salesforce CEO: Six Out of 10 Biggest Deals in 3Q Came from Agentforce

3.12.2025 г., 22:17 ч. UTC

Печалби

Salesforce Working to Add Voice to Agentforce, CEO Says

3.12.2025 г., 22:16 ч. UTC

Печалби

Salesforce CEO: Williams-Sonoma's Agentforce Makes Up 60% of Customer Chats

3.12.2025 г., 22:15 ч. UTC

Печалби

Salesforce CEO: Agentforce ARR Was $540M in 3Q

3.12.2025 г., 22:10 ч. UTC

Придобивния, сливания и поглъщания

EQB: Will Enter Into a Long-Term Strategic Relationship With Loblaw >EQB.T

3.12.2025 г., 22:09 ч. UTC

Придобивния, сливания и поглъщания

EQB: Agreed to Acquire PC Fincl From Loblaw >EQB.T

3.12.2025 г., 21:50 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

3.12.2025 г., 21:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

3.12.2025 г., 21:49 ч. UTC

Печалби

Salesforce Reports Mounting Profits. The Stock Is Rising. -- Barrons.com

3.12.2025 г., 21:23 ч. UTC

Печалби

Salesforce Raises Revenue Forecast as Agentforce Sales Top $500M

3.12.2025 г., 21:19 ч. UTC

Печалби

Salesforce Reports Mounting Profits. The Stock Is Rising. -- Barrons.com

3.12.2025 г., 21:06 ч. UTC

Печалби

Salesforce Reports Mixed Earnings. The Stock Is Rising. -- Barrons.com

3.12.2025 г., 21:04 ч. UTC

Печалби

Salesforce Sees Profitable Growth Framework Target of 50 by FY30 >CRM

3.12.2025 г., 21:04 ч. UTC

Печалби

Salesforce Targets $60 B Plus Organic Rev by FY30 >CRM

3.12.2025 г., 21:03 ч. UTC

Печалби

Salesforce Raises FY26 Oper Cash Flow Growth Guidance to 13% to 14% Y/Y >CRM

Сравнение с други в отрасъла

Ценова промяна

Day One Biopharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

170.5% нагоре

12-месечна прогноза

Среден 23.75 USD 170.5%

Висок 34 USD

Нисък 16 USD

Според 9 анализатори от Wall Street, предложили 12-месечна ценова цел за Day One Biopharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

9 ratings

Купи

Задържане

Продай

Според 9 анализатори, дали борсови рейтинги на Day One Biopharmaceuticals Inc през последните 3 месеца.

Техническа оценка

By Trading Central

6.26 / 7.47Подкрепа & съпротива

Recent bearish events outweigh bullish events.

All events are bullish.

All events are bearish.

Настроение

By Acuity

167 / 374 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.